Results 191 to 200 of about 541,695 (230)

Acute Myeloid Leukemia

Hematology/Oncology Clinics of North America, 2008
Acute myeloid leukemia (AML) is a heterogeneous group of leukemias that result from clonal transformation of hematopoietic precursors through the acquisition of chromosomal rearrangements and multiple gene mutations. As a result of highly collaborative clinical research by pediatric cooperative cancer groups worldwide, disease-free survival has ...
Jeffrey E, Rubnitz   +2 more
  +7 more sources

Acute Myeloid Leukemia

Hematology/Oncology Clinics of North America, 2009
The evolution of acute myeloid leukemia (AML) classification reflects greater understanding of the AML pathogenesis. The 2008 World Health Organization classification incorporated cytogenetic and molecular genetic findings and introduced important prognostic correlations.
Amy, Heerema-McKenney, Daniel A, Arber
openaire   +2 more sources

Acute Myeloid Leukemia

Hematology, 2001
AbstractThrough the hard work of a large number of investigators, the biology of acute myeloid leukemia (AML) is becoming increasingly well understood, and as a consequence, new therapeutic targets have been identified and new model systems have been developed for testing novel therapies.
F R, Appelbaum   +3 more
openaire   +2 more sources

Acute Myeloid Leukemia

Hematology, 2002
AbstractIn this chapter, Drs. Keating and Willman review recent advances in our understanding of the pathophysiology of acute myeloid leukemia (AML) and allied conditions, including the advanced myelodysplastic syndromes (MDS), while Drs. Goldstone, Avivi, Giles, and Kantarjian focus on therapeutic data with an emphasis on current patient care and ...
Francis J, Giles   +5 more
openaire   +2 more sources

Acute myeloid leukemia

2016
Acute myeloid leukemia (AML) accounts for approximately 20% of childhood leukemia, yet is responsible for a majority of the deaths from leukemia. Children present with a wide range of signs and symptoms, ranging from anemia to life-threatening coagulopathy, complications from tumor lysis syndrome or leukemic infiltration.
Arlene Redner, Rachel Kessel
openaire   +4 more sources

Angiogenesis in acute myeloid leukemia

Blood, 2000
We have read with interest the report of Padro et al[1][1] showing an increased angiogenesis in acute myeloid leukemia. Recently, other studies published in Blood also have shown that angiogenesis in acute myeloid leukemias is higher than in controls[2][2] and that it has an independent ...
DI RAIMONDO, FRANCESCO   +3 more
openaire   +4 more sources

Immunotherapy of Acute Myeloid Leukemia

Current Pharmaceutical Biotechnology, 2001
Most patients with acute myeloid leukemia (AML) respond initially to combination chemotherapy but later relapse. These patients often die from progressive disease or toxicities of further chemotherapy. At relapse, the patients' blasts are usually resistant to the drugs to which the patient has been exposed and frequently to other cytotoxic agents as ...
Arthur E. Frankel   +3 more
openaire   +3 more sources

Transplantation in Acute Myeloid Leukemia

Hematology/Oncology Clinics of North America, 2014
Acute myeloid leukemia (AML) is associated with poor outcome mainly because of relapse. The best antileukemic treatment is allogeneic stem cell transplantation. However, the associated significant nonrelapse mortality limits both the application and outcome of the procedure.
Tsila Zuckerman   +2 more
openaire   +3 more sources

Acute myeloid leukemia in adults

Current Treatment Options in Oncology, 2000
The treatment outcome for most adults with acute myeloid leukemia (AML) remains unacceptable. Additional agents or substitution of high-dose cytarabine for conventional-dose cytarabine during induction does not improve the remission rate or overall survival. There is substantial toxicity with high-dose cytarabine during induction.
Larry D. Cripe, Stuart Hinton
openaire   +3 more sources

Home - About - Disclaimer - Privacy